Beyond the Brain: How Blood Can Reveal the Hidden Signals of ALS
CynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as Alzheimer's or Parkinson's Diseases.
The aim is to provide clinically useful information on the presence and the severity of the disease; allowing both general and personalised therapies to be employed.
CynapseDx has been developing products to isolate proteins or cells from whole blood since 2012.
At the heart of our techniques is an antibody coated large ultra-dense magnetic particle that can force its way through the viscous, cell-rich media of blood to encounter and bind proteins. These can be free in plasma, or cell-associated.
Our primary focus is neurodegenerative diseases, such as Parkinson’s or Alzheimer’s Disease. Previous attempts to develop blood tests for these diseases have been unsuccessful, partly due to uncertainty over which biomarkers to choose and the likely scenario that there are only very low numbers of target proteins circulating in the blood stream. We have chosen to focus on oligomeric and aggregated forms of protein biomarkers and have demonstrated that our assays can measure these forms of biomarker proteins, when testing real patient blood samples.
We have a trial underway to demonstrate this is an effective tool that can identify patients with tremor symptoms that are misdiagnosed as Parkinson’s disease when they have another brain disorder. Using treatment costs published by NICE we have estimated that in the UK, the NHS is wasting some £52 million in treatments that do not work on the numbers misdiagnosed each year.
We plan to launch test kits to the academic community in 2018 and for clinical use in 2019.
Where Connections Spark Innovation
Synapse: Smarter Solutions for a Connected World
Precision. Intelligence. Synapse.
In recent diagnostic models, the concept of a “CynapseDx” has emerged to describe a functional interface where cellular synaptic activity and diagnostic signals converge—particularly in neurodegenerative diseases. This biological "diagnostic synapse" represents the dynamic zone where misfolded or aggregated proteins, such as SOD1, TDP-43, or FUS in ALS, interact with detection systems engineered to mimic immune recognition. By recreating this CynapseDx interface in vitro using antibody-coated magnetic particles, researchers can now detect pathological protein species directly from blood samples, capturing disease-relevant molecular events long before clinical symptoms fully manifest.
Communication is key!
Clear, consistent communication drives success. We prioritize open dialogue, ensuring alignment with your goals and seamless collaboration throughout every project.
Driving innovation together
Empowering teams to collaborate and innovate, creating impactful solutions that drive business growth and deliver lasting value.
Innovating for business success
Creating solutions that drive growth and long-term value.
Leading the future with innovation
We combine strategic insights and innovative solutions to drive business success, ensuring sustainable growth and competitive advantage in a dynamic market.
Plan, build, deliver insane value
Offering tailored strategies to drive growth and success.
A CynapseDx is not a structure you see under the microscope — it's the invisible diagnostic interface where pathological proteins meet precision capture, revealing the molecular whispers of diseases like ALS before they become clinical screams
Get Started
Our latest content
Check out what's new in our company !
100+ companies trust Gentaur to provide them with high-quality biochemistry services.
Join us and take your research to the next level.